U.S. Markets closed
  • S&P 500

    4,071.70
    -4.87 (-0.12%)
     
  • Dow 30

    34,429.88
    +34.88 (+0.10%)
     
  • Nasdaq

    11,461.50
    -20.90 (-0.18%)
     
  • Russell 2000

    1,892.84
    +11.16 (+0.59%)
     
  • Crude Oil

    80.34
    -0.88 (-1.08%)
     
  • Gold

    1,811.40
    -3.80 (-0.21%)
     
  • Silver

    23.35
    +0.51 (+2.25%)
     
  • EUR/USD

    1.0545
    +0.0017 (+0.1582%)
     
  • 10-Yr Bond

    3.5060
    -0.0230 (-0.65%)
     
  • Vix

    19.06
    -0.78 (-3.93%)
     
  • GBP/USD

    1.2270
    +0.0014 (+0.1104%)
     
  • USD/JPY

    134.3290
    -0.9770 (-0.7221%)
     
  • BTC-USD

    17,091.64
    +128.80 (+0.76%)
     
  • CMC Crypto 200

    404.33
    +2.91 (+0.72%)
     
  • FTSE 100

    7,556.23
    -2.26 (-0.03%)
     
  • Nikkei 225

    27,777.90
    -448.20 (-1.59%)
     

Cassava Sciences, Inc. (SAVA) Stock Moves -1.76%: What You Should Know

Cassava Sciences, Inc. (SAVA) closed at $43.07 in the latest trading session, marking a -1.76% move from the prior day. This move was narrower than the S&P 500's daily loss of 2.11%. Meanwhile, the Dow lost 1.54%, and the Nasdaq, a tech-heavy index, lost 0.3%.

Heading into today, shares of the company had gained 70.39% over the past month, outpacing the Medical sector's loss of 4.04% and the S&P 500's loss of 8.19% in that time.

Investors will be hoping for strength from Cassava Sciences, Inc. as it approaches its next earnings release. In that report, analysts expect Cassava Sciences, Inc. to post earnings of -$0.47 per share. This would mark a year-over-year decline of 95.83%.

Any recent changes to analyst estimates for Cassava Sciences, Inc. should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.

Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Cassava Sciences, Inc. currently has a Zacks Rank of #4 (Sell).

The Medical - Drugs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 81, which puts it in the top 33% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

To follow SAVA in the coming trading sessions, be sure to utilize Zacks.com.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Cassava Sciences, Inc. (SAVA) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research